Merav Fraenkel

mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

Merav Fraenkel, Mali Ketzinel‐Gilad, Yafa Ariav et al. · Diabetes · 2008 · 381 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes <i>SDHA</i>, <i>TMEM127</i>, <i>MAX</i>, and <i>SDHAF2</i> for Gene-Informed Prevention

Birke Bausch, Francesca Schiavi, Ying Ni et al. · JAMA Oncology · 2017 · 197 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour

Roy Eldor, Benjamin Gläser, Merav Fraenkel et al. · Clinical Endocrinology · 2011 · 131 citations

Medicine, Endocrinology, Oncology +17

Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)

Maralyn Druce, Gregory Kaltsas, Merav Fraenkel et al. · Hormone and Metabolic Research · 2009 · 108 citations

Medicine, Oncology, Pharmacotherapy +17

Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study

Dimitrios Thomas, Apostolos V. Tsolakis, Simona Grozinsky‐Glasberg et al. · European Journal of Endocrinology · 2012 · 96 citations · Full text

Medicine, Oncology, Pathology +17